Drug Promiscuity in PDB: Protein Binding Site Similarity Is Key

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Haupt, V Joachim ^a   Daminelli, Simone ^a   Schroeder, Michael ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' METHYLTHIOADENOSINE; ACARBOSE; ACTINONIN; AMPICILLIN; BENZAMIDINE; COLECALCIFEROL; DODECYL SULFATE; FARNESYL DIPHOSPHATE; GLUTATHIONE DISULFIDE; ISOBUTYLMETHYLXANTHINE; METHOTREXATE; N ACETYL 2,3 DIDEHYDRO 2 DEOXYNEURAMINIC ACID; NICOTINAMIDE; QUERCETIN; RETINOIC ACID; SINEFUNGIN; STAUROSPORINE; SURAMIN; TETRAHYDROBIOPTERIN; TETRAHYDROFOLIC ACID; UNCLASSIFIED DRUG; ZANAMIVIR; PROTEIN;

ARTICLE; BINDING SITE; CONFORMATION; CORRELATION ANALYSIS; DRUG INDICATION; DRUG PROMISCUITY; DRUG PROTEIN BINDING; DRUG REPOSITIONING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; HYDROPHOBICITY; LIGAND BINDING; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN DATA BANK; PROTEIN STRUCTURE; SCORING SYSTEM; SEQUENCE HOMOLOGY; CHEMISTRY; PROTEIN DATABASE;

ACARBOSE; BINDING SITES; DATABASES, PROTEIN; METHOTREXATE; PROTEINS; QUERCETIN;

EID: 84879269767     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065894     Document Type: Article

References (64)

1. Kola I, Landis J, (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3: 711-715.
2. Nobeli I, Favia AD, Thornton JM, (2009) Protein promiscuity and its implications for biotechnology. Nat Biotechnol 27: 157-167.
3. Hopkins AL, (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4: 682-690.
4. O'Connor KA, Roth BL, (2005) Finding new tricks for old drugs: an efficient route for public-sector drug discovery. Nat Rev Drug Discov 4: 1005-1014.
5. Haupt VJ, Schroeder M, (2011) Old friends in new guise: Repositioning of known drugs with structural bioinformatics. Brief Bioinform 12: 312-326.
6. Mencher SK, Wang LG, (2005) Promiscuous drugs compared to selective drugs (promiscuity can be a virtue). BMC Clin Pharmacol 5: 3.
7. Xie L, Xie L, Kinnings SL, Bourne PE, (2012) Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 52: 361-379.
8. Sanseau P, Agarwal P, Barnes MR, Pastinen T, Richards JB, et al. (2012) Use of genome-wide association studies for drug repositioning. Nat Biotechnol 30: 317-320.
9. Dudley JT, Sirota M, Shenoy M, Pai RK, Roedder S, et al. (2011) Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med 3: 96ra76.
10. Pujol A, Mosca R, Farrs J, Aloy P, (2010) Unveiling the role of network and systems biology in drug discovery. Trends Pharmacol Sci 31: 115-123.
11. Kalinina OV, Wichmann O, Apic G, Russell RB, (2011) Combinations of protein-chemical complex structures reveal new targets for established drugs. PLoS Comput Biol 7: e1002043.
12. Daminelli S, Haupt VJ, Reimann M, Schroeder M, (2012) Drug repositioning through incomplete bi-cliques in an integrated drug-target-disease network. Integr Biol (Camb) 4: 778-788.
13. Kinnings SL, Xie L, Fung KH, Jackson RM, Xie L, et al. (2010) The mycobacterium tuberculosis drugome and its polypharmacological implications. PLoS Comput Biol 6: e1000976.
14. Konc J, Cesnik T, Konc JT, Penca M, Janei D, (2012) Probis-database: precalculated binding site similarities and local pairwise alignments of pdb structures. J Chem Inf Model 52: 604-612.
15. Xie L, Xie L, Bourne PE, (2009) A unified statistical model to support local sequence order independent similarity searching for ligand-binding sites and its application to genome-based drug discovery. Bioinformatics 25: i305-i312.
16. Kellenberger E, Schalon C, Rognan D, (2008) How to measure the similarity between protein ligandbinding sites? Curr Comput-Aid Drug 4: 209-220.
17. Schalon C, Surgand JS, Kellenberger E, Rognan D, (2008) A simple and fuzzy method to align and compare druggable ligand-binding sites. Proteins 71: 1755-1778.
18. Liu T, Altman RB, (2011) Using multiple microenvironments to find similar ligand-binding sites: application to kinase inhibitor binding. PLoS Comput Biol 7: e1002326.
19. Azzaoui K, Hamon J, Faller B, Whitebread S, Jacoby E, et al. (2007) Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem 2: 874-880.
20. Hopkins AL, Mason JS, Overington JP, (2006) Can we rationally design promiscuous drugs? Curr Opin Struct Biol 16: 127-136.
21. Morphy R, Rankovic Z, (2007) Fragments, network biology and designing multiple ligands. Drug Discov Today 12: 156-160.
22. Leeson PD, Springthorpe B, (2007) The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6: 881-890.
23. Peters JU, Schnider P, Mattei P, Kansy M, (2009) Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent roche compounds. ChemMedChem 4: 680-686.
24. Mestres J, Gregori-Puigjan E, Valverde S, Sol RV, (2009) The topology of drug-target interaction networks: implicit dependence on drug properties and target families. Mol BioSyst 5: 1051-1057.
25. Gleeson MP, Hersey A, Montanari D, Overington J, (2011) Probing the links between in vitro potency, admet and physicochemical parameters. Nat Rev Drug Discov 10: 197-208.
26. Leach AR, Hann MM, (2011) Molecular complexity and fragment-based drug discovery: ten years on. Curr Opin Chem Biol 15: 489-496.
27. Hann MM, Leach AR, Harper G, (2001) Molecular complexity and its impact on the probability of finding leads for drug discovery. J Chem Inf Comput Sci 41: 856-864.
28. McGovern SL, Caselli E, Grigorieff N, Shoichet BK, (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45: 1712-1722.
29. McGovern SL, Helfand BT, Feng B, Shoichet BK, (2003) A specific mechanism of nonspecific inhibition. J Med Chem 46: 4265-4272.
30. Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, et al. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 50: 2385-2390.
31. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, et al. (2000) The Protein Data Bank. Nucleic Acids Res 28: 235-242.
32. Heinrich JC, Tuukkanen A, Schroeder M, Fahrig T, Fahrig R, (2011) RP101 (brivudine) binds to heat shock protein HSP27 (HSPB1) and enhances survival in animals and pancreatic cancer patients. J Cancer Res Clin Oncol 137: 1349-1361.
33. Kroeze W, Roth B (2012) Polypharmacological drugs:magic shotguns for psychiatric diseases. Polypharmacology in Drug Discovery: 133-148.
34. Overington JP, Al-Lazikani B, Hopkins AL, (2006) How many drug targets are there? Nat Rev Drug Discov 5: 993-996.
35. Finn RD, Mistry J, Tate J, Coggill P, Heger A, et al. (2010) The pfam protein families database. Nucleic Acids Res 38: D211-D222.
36. Liu T, Lin Y, Wen X, Jorissen RN, Gilson MK, (2007) BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 35: D198-D201.
37. Xie L, Evangelidis T, Xie L, Bourne PE, (2011) Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. PLoS Comput Biol 7: e1002037.
38. Kellenberger E, Muller P, Schalon C, Bret G, Foata N, et al. (2006) sc-PDB: an annotated database of druggable binding sites from the protein data bank. J Chem Inf Model 46: 717-727.
39. Lipinski CA, (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249.
40. Bakheet TM, Doig AJ, (2009) Properties and identification of human protein drug targets. Bioinformatics 25: 451-457.
41. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP, (2008) Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 8: 1384-1394.
42. Zhou X, Tan TC, Valiyaveettil S, Go ML, Kini RM, et al. (2008) Structural characterization of myotoxic ecarpholin s from echis carinatus venom. Biophys J 95: 3366-3380.
43. Gnther S, Senger C, Michalsky E, Goede A, Preissner R, (2006) Representation of target-bound drugs by computed conformers: implications for conformational libraries. BMC Bioinformatics 7: 293.
44. Brandt W, Haupt VJ, Wessjohann LA, (2010) Cheminformatic analysis of biologically active macrocycles. Curr Top Med Chem 10: 1361-1379.
45. Xie L, Bourne PE, (2007) A robust and efficient algorithm for the shape description of protein structures and its application in predicting ligand binding sites. BMC Bioinformatics 8Suppl 4: S9.
46. Xie L, Bourne PE, (2008) Detecting evolutionary relationships across existing fold space, using sequence order-independent profile-profile alignments. Proc Natl Acad Sci U S A 105: 5441-5446.
47. van Dijk ADJ, Boelens R, Bonvin AMJJ, (2005) Data-driven docking for the study of biomolecular complexes. FEBS J 272: 293-312.
48. Najmanovich R, Kurbatova N, Thornton J, (2008) Detection of 3d atomic similarities and their use in the discrimination of small molecule protein-binding sites. Bioinformatics 24: i105-i111.
49. Rahman SA, Bashton M, Holliday GL, Schrader R, Thornton JM, (2009) Small molecule subgraph detector (smsd) toolkit. J Cheminform 1: 12.
50. Zhang Y, Skolnick J, (2005) TM-align: a protein structure alignment algorithm based on the tmscore. Nucleic Acids Res 33: 2302-2309.
51. Bello AR, Nare B, Freedman D, Hardy L, Beverley SM, (1994) Ptr1: a reductase mediating salvage of oxidized pteridines and methotrexate resistance in the protozoan parasite leishmania major. Proc Natl Acad Sci U S A 91: 11442-11446.
52. Boly R, Gras T, Lamkami T, Guissou P, Serteyn D, et al. (2011) Quercetin inhibits a large panel of kinases implicated in cancer cell biology. Int J Oncol 38: 833-842.
53. Zhu F, Han B, Kumar P, Liu X, Ma X, et al. (2010) Update of TTD: Therapeutic target database. Nucleic Acids Res 38: D787-D791.
54. Davis AP, King BL, Mockus S, Murphy CG, Saraceni-Richards C, et al. (2011) The comparative toxicogenomics database: update 2011. Nucleic Acids Res 39: D1067-D1072.
55. Knox C, Law V, Jewison T, Liu P, Ly S, et al. (2011) DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 39: D1035-D1041.
56. Li Q, Cheng T, Wang Y, Bryant SH, (2010) PubChem as a public resource for drug discovery. Drug Discov Today 15: 1052-1057.
57. Guha R, Howard MT, Hutchison GR, Murray-Rust P, Rzepa H, et al. (2006) The blue obeliskinteroperability in chemical informatics. J Chem Inf Model 46: 991-998.
58. O'Boyle NM, Morley C, Hutchison GR, (2008) Pybel: a python wrapper for the openbabel cheminformatics toolkit. Chem Cent J 2: 5.
59. Gold ND, Jackson RM, (2006) Fold independent structural comparisons of protein-ligand binding sites for exploring functional relationships. J Mol Biol 355: 1112-1124.
60. Painter J, Merritt EA, (2004) mmLib Python toolkit for manipulating annotated structural models of biological macromolecules. J Appl Crystallogr 37: 174-178.
61. Xie L, Wang J, Bourne PE, (2007) In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLoS Comput Biol 3: e217.
62. Xie L, Li J, Xie L, Bourne PE, (2009) Drug discovery using chemical systems biology: identification of the protein-ligand binding network to explain the side effects of cetp inhibitors. PLoS Comput Biol 5: e1000387.
63. Rice P, Longden I, Bleasby A, (2000) Emboss: the european molecular biology open software suite. Trends Genet 16: 276-277.
64. Bottegoni G, Rocchia W, Recanatini M, Cavalli A, (2006) Aclap, autonomous hierarchical agglomerative cluster analysis based protocol to partition conformational datasets. Bioinformatics 22: e58-e65.